Structure‐Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5‐ b ]pyridin‐2‐one‐Based p38 MAP Kinase Inhibitors: Part 1-Reference-Cited by-同舟云学术

Structure‐Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5‐ b ]pyridin‐2‐one‐Based p38 MAP Kinase Inhibitors: Part 1

Published:2019-04-18 Issue:10 Volume:14 Page:1022-1030
ISSN:1860-7179
Container-title:ChemMedChem
language:en
Short-container-title:ChemMedChem

Author:

Kaieda Akira¹^ORCID,Takahashi Masashi¹^ORCID,Fukuda Hiromi¹,Okamoto Rei¹,Morimoto Shinji¹,Gotoh Masayuki¹,Miyazaki Takahiro¹,Hori Yuri¹,Unno Satoko¹,Kawamoto Tomohiro¹^ORCID,Tanaka Toshimasa¹^ORCID,Itono Sachiko¹,Takagi Terufumi¹,Sugimoto Hiroshi¹^ORCID,Okada Kengo¹,Snell Gyorgy²,Bertsch Ryan²,Nguyen Jasmine²^ORCID,Sang Bi‐Ching²,Miwatashi Seiji¹

Affiliation:

1. Pharmaceutical Research DivisionTakeda Pharmaceutical Company Limited 26-1, Muraoka-higashi 2-chome, Fujisawa Kanagawa 251-8555 Japan

2. Takeda California 10410 Science Center Drive San Diego CA 92121 USA

Publisher

Wiley

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics,Molecular Medicine,Drug Discovery,Biochemistry,Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cmdc.201900129

Reference38 articles.

1. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis

2. p38 Mitogen-Activated Protein Kinase (MAPK) in Rheumatoid Arthritis